公司概覽
業務類別 Biotechnology
業務概覽 Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
公司地址 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
電話號碼 +1 858 558-2871
傳真號碼 +1 858 212-0513
公司網頁 https://www.acadia.com
員工數量 798
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Elizabeth H.Z. Thompson, PhD Executive Vice President and Head of Research and Development 美元 281.88K 25/04/2025
Mr. Thomas A. Garner Executive Vice President and Chief Commercial Officer -- 25/04/2025
Ms. Catherine Owen Adams Director and Chief Executive Officer 美元 245.77K 26/02/2026
Mr. James K. Kihara Senior Vice President, Finance, Controller and Chief Accounting Officer -- 26/02/2026
Mr. Mark C. Schneyer Executive Vice President and Chief Financial Officer 美元 518.47K 26/02/2026
Ms. Jennifer J. Rhodes Executive Vice President, Chief Legal Officer and Secretary 美元 478.03K 25/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Julian C. Baker Independent Director 26/02/2026
Ms. Laura A. Brege Independent Director 26/02/2026
Mr. James M. Daly Independent Director 26/02/2026
Dr. Stephen R. Biggar,M.D.,PhD Chairman of the Board 26/02/2026
Mr. Jonathan Poole Director 05/03/2026
Dr. Edmund P. Harrigan, M.D. Independent Director 26/02/2026
Ms. Catherine Owen Adams Director and Chief Executive Officer 26/02/2026
Dr. Elizabeth A. Garofalo, M.D. Independent Director 26/02/2026
Dr. Adora Ndu, Pharm.D. Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:17)
代號 名稱 佔比% 持有日期
AVSUAvantis Responsible US Equity ETF0.0002%28/02/2026
AVUSAvantis US Equity ETF0.0002%28/02/2026
FEACFidelity Enhanced U.S. All-Cap Eq ETF0.0001%27/02/2026
AVTMAvantis Total Equity Markets ETF0.0001%28/02/2026
HDGProShares Hedge Replication0.0001%27/02/2026
AVIEAvantis Inflation Focused Equity ETF0.0001%28/02/2026
GTPEGoldman Sachs MSCI Wld Priv Eq RtTrkrETF0.00005%27/02/2026
AIEQAI Powered Equity ETF<0.000001%03/05/2023
AVUVAvantis US Small Cap Value ETF<0.000001%15/11/2025
AWEGAlger Weatherbie Enduring Growth ETF<0.000001%16/12/2025
CAFGPacer US Small Cap Cash Cows Gr Ldrs ETF<0.000001%23/06/2025
EESWisdomTree US SmallCap Earnings ETF<0.000001%11/12/2025
FSMDFidelity Small-Mid Multifactor ETF<0.000001%20/02/2026
FYCFirst Trust Small Cap Gr AlphaDEX® ETF<0.000001%07/10/2025
FYXFirst Trust Small Cap Core AlphaDEX® ETF<0.000001%07/10/2025
GPTIntelligent Alpha Atlas ETF<0.000001%10/06/2025
HKNDHumankind US Stock ETF<0.000001%24/11/2025
IJSiShares S&P Small-Cap 600 Value ETF<0.000001%19/12/2025
MNTLTema Neuroscience and Mental Health ETF<0.000001%05/08/2025
NXTISimplify Next Intangible Core Index ETF<0.000001%31/12/2025
  1    2    3    4    5   6    7  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.